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Objective. Skin and musculoskeletal involvement are frequently present early in diffuse cutaneous systemic sclerosis
(dcSSc). The current study examined the correlates for skin and musculoskeletal measures in a 1-year longitudinal
observational study.
Methods. Patients with dcSSc were recruited at 4 US centers and enrolled in a 1-year study. Prespeciﬁed and
standardized measures included physician and patient assessments of skin involvement, modiﬁed Rodnan skin score
(MRSS), durometer score, Health Assessment Questionnaire disability index, serum creatine phosphokinase, tender joint
counts, and presence/absence of tendon friction rubs, small joint contractures, and large joint contractures. Additionally,
physician and patient global health assessments and health-related quality of life assessments were recorded. Correla-
tions were computed among the baseline global assessments, skin variables, and musculoskeletal variables. Using the
followup physician and patient anchors, effect sizes were calculated.
Results. A total of 200 patients were studied: 75% were women, mean  SD age was 50.0  11.9 years, and mean  SD
disease duration from ﬁrst non–Raynaud’s phenomenon symptom was 1.6  1.4 years. Physician global health assess-
ment had large correlations with MRSS (r 0.60) and physician-reported skin involvement visual analog scale in the last
month (r  0.74), whereas patient global assessment had large correlations with MRSS, the Short Form 36 health survey
physical component scale, skin interference, and skin involvement in the last month (r  0.37–0.72). Four of 9 skin
variables had moderate to large effect sizes (0.51–1.09).
Conclusion. Physician and patient global assessments have larger correlations with skin measures compared to
musculoskeletal measures. From a clinical trial perspective, skin variables were more responsive to change than
musculoskeletal variables over a 1-year period, although both provide complementary information.
INTRODUCTION
Systemic sclerosis (SSc; scleroderma) is a connective tis-
sue disease, hallmarks of which include thickening of the
skin, vascular obliteration, and involvement of internal
organ systems, including the cardiopulmonary, renal, and
gastrointestinal systems (1). Diffuse cutaneous SSc (dcSSc)
is the form of the disease that includes proximal skin
thickening, earlier occurrence of more severe organ in-
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volvement, and association with high mortality and a sig-
niﬁcant impairment in health-related quality of life
(HRQOL) (2–5).
Symptomatic musculoskeletal and skin disease are fre-
quent manifestations of dcSSc and have detrimental im-
pact on patients’ disease burden (6–10). For example, us-
ing a patient-reported symptom burden index, Kallen et al
found that hand involvement and skin problems were
reported as the second and third most burdensome symp-
toms (6). Bassel et al surveyed 464 patients with SSc and
found that 5 of the 8 most frequently experienced symp-
toms were related to musculoskeletal or skin involvement
(8). Other groups have found skin features to be among the
most commonly mentioned SSc-related problems (9,10).
The Combined Response Index for Systemic Sclerosis
(CRISS) study is a 200-patient, observational 1-year longi-
tudinal cohort of patients with dcSSc and a disease dura-
tion of 5 years. CRISS seeks to develop a composite
index for SSc by including various measurements of organ
system involvement and function (11). Our goal was to
develop a data-based approach to disease measurement,
particularly in the context of future interventional trials.
We used data from the CRISS cohort to 1) assess the
correlates of baseline measures for skin and musculoskel-
etal involvement, and 2) evaluate the responsiveness to
change of skin and musculoskeletal measures over 1 year.
PATIENTS AND METHODS
Patients. dcSSc was deﬁned as skin thickening proxi-
mal, as well as distal, to the elbows or knees with or
without involvement of the face and neck, and early dis-
ease was considered 5 years since the onset of the ﬁrst
sign or symptom of SSc, other than Raynaud’s phenome-
non. The study was approved by the institutional review
boards of the participating centers.
Outcome measures. The CRISS study included the core
set outcome measures proposed through a consensus
methodology as previously described (12). These measures
cover 11 domains: skin, musculoskeletal, cardiac, pulmo-
nary, gastrointestinal, renal, Raynaud’s phenomenon, dig-
ital ulcers, HRQOL and function, global health, and bio-
markers.
Skin measures. Physician- and patient-reported mea-
sures. There were 3 physician and 4 patient assessments
of skin involvement employed in the study. Both physi-
cians and patients were asked to indicate “activity” of skin
involvement in the last month and in the last year, respec-
tively, on a scale of 0–10, where 0 indicated “not active”
and 10 denoted “extremely active.” Physicians also pro-
vided an assessment of the skin severity on a scale of 1
(very mild) to 5 (very severe). These scales were created for
CRISS as they were considered to be important for assess-
ing activity and severity of skin involvement in early dis-
ease. Additionally, patients provided assessments of skin
condition interference with daily activities in the last
month and in the last year, respectively, recorded on a
scale from 0 (indicating that the skin involvement “does
not limit activity”) to 10 (“very severe limitation”).
Objective measures. The modiﬁed Rodnan skin score
(MRSS) is a clinical measure of the extent and severity of
skin thickening (13–15). Skin thickening is assessed in 17
body areas: ﬁngers, hands, forearms, arms, feet, legs, and
thighs (bilaterally), and face, chest, and abdomen (singu-
larly) (16). Each area is scored from 0 to 3, with 0 repre-
senting normal skin and 3 being severe thickening. Cumu-
latively, MRSS ranges from 0 (no thickening) to 51 (severe
thickening in all 17 areas) (15).
The durometer is a handheld device that measures the
hardness of a surface. It has been used to measure skin
hardness in patients with SSc and was found to be feasi-
ble, reliable, and responsive to change in a recent clinical
trial (17). Durometer measurements in patients with SSc
typically range from approximately 4 durometer units
(DUs) for uninvolved skin to around 70 DUs for maximally
involved skin (18). Durometry has been shown to have
high correlation (r  0.69) with MRSS in a pilot study and
was included as an objective measure (17).
Musculoskeletal measures. Patient-reported measure.
The Health Assessment Questionnaire (HAQ) disability
index (DI) is a disease-speciﬁc, arthritis-targeted measure
intended for assessing functional ability in arthritis (19). It
is a self-administered 20-question instrument that assesses
a patient’s level of functional ability and includes ques-
tions about both upper and lower extremities. The score is
determined by summing the highest item score in each of
the 8 domains and dividing the sum by 8, resulting in a
score ranging from 0 (no disability) to 3 (severe disability)
(20). Several studies have reported the reliability, validity,
and prognostic value of the HAQ DI as a measure of mus-
culoskeletal involvement in SSc (20–22).
Laboratory-reported measures. Serum creatine phos-
phokinase (CPK) was assessed using the local laboratory.
In a subset of patients, antinuclear antibody, anticentrom-
ere antibody, and anti-Scl 70 antibody were recorded
based on measurements by local laboratories.
Physical examination measures. The presence or ab-
sence of palpable tendon friction rubs (TFRs) was assessed
at baseline and at 1-year and were coded as present/absent
Signiﬁcance & Innovations
● In an early diffuse cutaneous systemic sclerosis
(dcSSc) population, patient and physician global
assessments of disease have greater correlations
with skin variables than with musculoskeletal
variables.
● The current study supports the use of different
patient-reported and objective measures (such as
modiﬁed Rodnan skin score, skin involvement in
the last month, and the Health Assessment Ques-
tionnaire disability index) as clinical outcome
measures in early dcSSc.
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at each site (23). The sites included bilateral wrists, knees,
ankles, as well as other sites where TFRs were noted
during clinical examination (e.g., ﬁngers). Small and large
joint contractures were assessed bilaterally. Small joint
contractures were evaluated in the ﬁngers and wrists, and
large joint contractures were assessed in the knees, elbows,
and shoulders. Tender joint counts were evaluated bilat-
erally at the following joints: shoulders, elbows, wrists,
metacarpophalangeals (as a group), proximal interphalan-
geals (as a group), hips, knees, ankles, and metatarsopha-
langeals.
Global health and HRQOL measures. We determined
baseline global assessment of overall SSc using physician
and patient assessments of health in the week prior to the
study visit. In both cases, the patient or physician was asked
to rate the patient’s overall health in the past week on a scale
from 0 (excellent) to 10 (extremely poor). The generic
HRQOL was evaluated using the Short Form 36 (SF-36)
health survey physical component score (PCS) and the men-
tal component score (MCS). The SF-36 has been previously
validated for use in SSc (20). A modiﬁed Likert scale (tran-
sition health question) was employed for physicians and
patients at the 1-year followup to determine the change in
overall condition in the past year on a scale from 1 (“much
better”) to 5 (“much worse”). Responses of 1 or 2 were con-
sidered an overall improvement, ratings of 4 or 5 were con-
sidered a decline in health, and a rating of 3 meant that there
was no appreciable change in overall health.
Table 1. Baseline characteristics of 200 patients with early diffuse systemic sclerosis*
Baseline characteristic No. Value IQR
Demographics
Age, years 200 50.0  11.9 42.9–37.6
BMI, kg/m2 177 25.5  5.5 21.6–28.5
Disease duration, years 193 1.6  1.4 0.5–2.7
Women, % 150 75 NA
Race, %
White 157 79 NA
African American 18 9 NA
Asian 16 8 NA
Other 9 4 NA
Hispanic 19 10 NA
Physician global assessment 175 4.3  2.2 3.0–6.0
Patient global assessment 177 3.9  2.7 2.0–6.0
SF-36 PCS 174 37.9  12.8 28.3–46.4
SF-36 MCS 174 44.2  6.1 39.9–48.9
Skin involvement
Physician reported
In the last month (0–10) 183 4.0  2.9 1.5–6.0
In the last year (0–10) 178 4.7  3.0 2.0–7.0
Skin severity (1–5) 200 4.1  1.5 3.0–5.0
Patient reported
Skin condition interference with daily activities in last month (0–10) 157 3.9  3.2 1.0–7.0
Skin condition interference with daily activities in last year (0–10) 157 4.0  3.2 1.0–7.0
Skin involvement in the last month (0–10) 171 3.3  3.2 0.0–5.0
Skin involvement in the last year (0–10) 172 4.6  3.3 2.0–7.3
Physical examination
Modiﬁed Rodnan skin score 200 20.6  10.1 13.0–28.0
Durometer, DU 135 266.3  66.6 219.2–307.9
Skin progression rate 193 63.8  184.7 7.1–48.9
Musculoskeletal
Patient reported
HAQ DI 200 1.0  0.8 0.1–1.5
Laboratory/serology
Serum creatine phosphokinase, IU/liter 161 167.1  403.6 49.0–160.0
ANA positive 151 83 –
Anticentromere positive 103 12 –
Anti-Scl 70 positive 148 29 –
Physical examination
Tendon friction rubs, % 189 24 NA
Small joint contractures, % 182 52 NA
Large joint contractures, % 182 26 NA
Tender joint count 198 1.3  2.7 0.0–1.8
* Values are the mean  SD unless indicated otherwise. IQR  interquartile range; BMI  body mass index; NA  not applicable; SF-36  Short Form
36 health survey; PCS physical component score; MCSmental component score; DU durometer units; HAQHealth Assessment Questionnaire;
DI  disability index; ANA  antinuclear antibody.
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Statistical analysis. We calculated summary statistics
for all clinical and demographic variables collected on the
subjects enrolled in the CRISS study. For the continuous
variables we computed the mean, SD, and interquartile
range (difference between the 75th and the 25th percen-
tile). For the binary or discrete variables, we computed the
percentage of patients satisfying a given condition.
To determine whether there was an association between
the different skin and musculoskeletal variables, we com-
puted Pearson’s (and when appropriate Spearman’s) cor-
relations among the skin and the musculoskeletal vari-
ables. Pearson’s correlation coefﬁcients were interpreted
as proposed by Cohen: 0.0–0.10 indicates negligible cor-
relation, 0.10–0.23 indicates a small correlation coefﬁ-
cient, 0.24–0.36 indicates a moderate correlation, and
0.37 indicates a large correlation coefﬁcient (24).
For each skin and musculoskeletal variable we also eval-
uated responsiveness to change through the effect size (ES)
using the transition health question (see Global health and
HRQOL measures above). ES was calculated by deriving
the mean change from baseline to followup for the group of
patients whose SSc condition improved based on physi-
cian/patient assessment and dividing it by the baseline SD.
Cohen’s “rule-of-thumb” for interpreting ES is that a value
of 0.20–0.49 represents a small change, 0.50–0.79 a me-
dium change, and 0.80 a large change (25).
Finally, we considered logistic regression models for the
log-odds of being improved according to physician and pa-
tient assessment, respectively. In each logistic regression, the
log-odds were regressed on the change in each variable.
RESULTS
Outcomes. The CRISS study enrolled 200 participants
with early dcSSc; 150 were women (75%), with a mean 
SD age of 50.0  11.9 years, and a mean  SD body mass
index of 25.5  5.5 kg/m2. The majority of the participants
were white (79%) and reported non-Hispanic ethnicity
(90%). The mean SD disease duration assessed from ﬁrst
non–Raynaud’s phenomenon sign or symptom was 1.6 
1.4 years. See Table 1 for additional details of the cohort.
Patient and physician global assessments and HRQOL.
The mean  SD physician-reported global assessment of
health (on a 0–10 scale) was 4.3  2.2, while the mean 
SD patient-reported global assessment was 3.9  2.7. The
mean SD for the SF-36 PCS and MCS scores were 37.9
12.8 and 44.2  6.1, respectively, indicating a moderate to
severe level of physical and mental well-being.
Skin involvement. Physician- and patient-reported as-
sessments of skin involvement on a 0–10 visual analog
scale (VAS) revealed that, on average, participants had
moderate skin activity in the last year (Table 1). Mean 
SD baseline MRSS was 20.6  10.1, while mean  SD
baseline durometer was 266.3  66.6 DUs.
Musculoskeletal involvement. Mean SD baseline HAQ
DI was 1.0  0.8, mean  SD baseline serum CPK was
167.1  403.6 IU/liter, and mean  SD number of tender
joints was 1.3  2.7. Twenty-four percent of the partici-
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Figure 1. Pairwise scatterplot of modiﬁed Rodnan skin scores
and durometer scores (correlation: r  0.69).
Table 3. Baseline correlates of musculoskeletal variables*
Musculoskeletal variables
Physician
global
health
Patient
global
health
SF-36
PCS
SF-36
MCS HAQ DI CPK
Tendon
friction
rubs
Small joint
contractures
Large joint
contractures
Tender
joint
count
Patient reported
HAQ DI 0.43 0.57 0.79 0.29 – 0.06 0.25 0.22 0.36 0.23
Laboratory
Serum CPK 0.19 0.13 0.15 0.06 0.04 – 0.29 0.00 0.14 0.01
Physical examination
Tendon friction rubs 0.36 0.21 0.24 0.09 0.06 0.29 – 0.18 0.21 0.10
Small joint contractures 0.36 0.13 0.19 0.09 0.07 0.00 0.18 – 0.50 0.20
Large joint contractures 0.39 0.28 0.29 0.01 0.07 0.14 0.21 0.50 – 0.14
Tender joint count 0.31 0.21 0.32 0.00 0.09 0.01 0.10 0.20 0.14 –
* SF-36 Short Form 36 health survey; PCS physical component score; MCSmental component score; HAQ Health Assessment Questionnaire;
DI  disability index; CPK  creatine phosphokinase.
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pants had tendon friction rubs, 26% had large joint con-
tractures, and 52% had small joint contractures.
Correlation coefﬁcients for skin and musculoskeletal
variables. There was a large correlation (r 0.43) between
physician and patient global assessments at baseline. In
addition, physician global assessment and patient global
assessment had large (r  0.53 and r  0.72) negative
correlations with SF-36 PCS, respectively. Both global as-
sessments had negligible correlation with SF-36 MCS.
Skin measures. The physician global health assessment
VAS had large correlations with the physician assessment
of skin involvement in the last month VAS (r  0.74) and
with the patient reported skin involvement in the last
month VAS (r  0.44) (Table 2). MRSS had a large corre-
lation with the physician-reported global health (r 0.60),
SF-36 PCS (r  0.43), and many of the skin-related phy-
sician- and patient-reported variables, as well durometer
readings (r  0.69) (Figure 1). Other correlations are listed
in Table 2.
Musculoskeletal measures. There were large correla-
tions between HAQ DI and SF-36 PCS (r  0.79), physi-
cian global health assessment and baseline large joint con-
tractures (r  0.39), and between both physician and
patient global health assessments and HAQ DI (r  0.43
and r  0.57, respectively). There were small to moderate
correlations between the remaining baseline musculoskel-
etal variables and the global health assessments (Table 3).
Responsiveness to change. One-year data were available
for 150 of the 200 study participants. Based on the physi-
cian assessment for change in overall SSc condition in the
previous year, 58.6% of patients were categorized as im-
proved, 26.9% as worsened, and 14.4% as unchanged. The
patients’ assessments of change in health over 1 year re-
vealed that 56.7% believed that the overall condition of
their SSc improved, 26.8% reported that their condition
Table 4. Responsiveness to change of skin and
musculoskeletal variables over 1 year (effect size)*
Variable
Physician
anchor
Patient
anchor
Skin
Physician reported
Skin involvement in last
month
0.66 0.51
Skin involvement in last
year
0.56 0.54
Skin severity 1.09 0.83
Patient reported
Skin condition interference
with daily activities in
last month
0.53 0.34
Skin condition interference
with daily activities in
last year
0.38 0.26
Skin involvement in last
month
0.12 0.22
Skin involvement in last
year
0.03 0.03
Physical examination
Modiﬁed Rodnan skin
score
0.58 0.65
Durometer 0.02 0.25
Musculoskeletal
Patient reported
HAQ DI 0.10 0.07
Laboratory
Serum creatine
phosphokinase
0.23 0.26
Physical examination
Tender joint count 0.33 0.31
* Small joint contractures, large joint contractures, and tendon fric-
tion rubs are not included as they are binary variables. HAQ 
Health Assessment Questionnaire; DI  disability index.
Table 5. Logistic regression for the log-odds of being improved according to physician or patient
assessment*
Change in characteristic
Physician assessment,
OR (95% CI)
Patient assessment,
OR (95% CI)
Physician global assessment 0.65 (0.51–0.82)† 0.68 (0.53–0.88)†
Physician skin involvement last month 0.76 (0.63–0.92)† 0.81 (0.66–0.99)†
Physician skin involvement last year 0.86 (0.71–1.03) 0.87 (0.71–1.07)
Skin severity (physician reported) 0.65 (0.48–0.88)† 0.86 (0.65–1.14)
SF-36 PCS 1.07 (1.01–1.14)† 1.03 (0.98–1.07)
SF-36 MCS 0.98 (0.92–1.05) 1.02 (0.96–1.09)
Durometer 1.00 (0.99–1.00) 0.99 (0.98–1.00)
MRSS 0.94 (0.89–0.99)† 0.88 (0.81–0.95)†
HAQ DI 0.56 (0.27–1.17) 0.69 (0.34–1.36)
CPK 1.00 (0.99–1.00) 0.99 (0.98–1.00)†
Total joint count 0.97 (0.83–1.12) 1.00 (0.86–1.17)
Patient-reported skin involvement last month 0.92 (0.79–1.06) 1.02 (0.89–1.17)
Patient-reported skin involvement last year 0.96 (0.85–1.09) 1.04 (0.92–1.18)
Skin interference with daily activities last month 0.97 (0.79–1.19) 0.87 (0.71–1.07)
Skin interference with daily activities last year 1.01 (0.87–1.18) 0.97 (0.83–1.13)
* OR odds ratio; 95% CI 95% conﬁdence interval; SF-36 Short Form 36 health survey; PCS physical component
score; MCSmental component score; MRSSmodiﬁed Rodnan skin score; HAQ Health Assessment Questionnaire;
DI  disability index; CPK  creatine phosphokinase.
† P  0.05.
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declined, and 16.5% responded that their condition stayed
the same.
Physician assessments of skin involvement in the past
month and year, respectively, and MRSS had medium ES
(0.51– 0.66) (Table 4). Physician assessment of overall skin
severity had a large ES (0.83–1.09). For musculoskeletal
variables, the ES were negligible (HAQ DI [0.07–0.10]) to
small (0.23–0.33) (Table 4).
Of the objective outcomemeasures, 3 items are measures
of disease activity, deﬁned as items that are reversible
(either with treatment or spontaneously), i.e., serum CPK,
tendon friction rubs, and tender joint count (26). Other
objective measures, such as MRSS and durometer, assess
severity (combination of activity and damage). Measures of
activity were not more responsive than measures of sever-
ity (Table 4).
Logistic regression based on physician and patient as-
sessments of improvement. In the univariate models, im-
provements in physician global assessment, MRSS, physi-
cian-reported skin severity, and physician evaluation of
skin involvement in the last month are signiﬁcantly asso-
ciated with the odds of being improved as rated by physi-
cian. As an example, for a 1-unit increase in MRSS from
baseline to the 1-year followup, there is a 6% decrease in
the odds that the patient is rated improved by a physician
(Table 5).
When considering patient self-assessment of disease at
1-year followup, our analysis revealed a signiﬁcant asso-
ciation between the odds that the patient rated himself/
herself as improved and improvements in physician global
assessment, physician assessment of skin involvement last
month, MRSS, and CPK. In particular, for a 1-unit increase
in MRSS from baseline to 1-year followup there is a 12%
decrease in the odds that the patient considered himself or
herself as improved.
DISCUSSION
Diffuse cutaneous SSc is associated with poor HRQOL and
high mortality, with skin and musculoskeletal symptoms
being of particular importance to patients with this disease
(4–6,9,27). There is a need to carefully evaluate the out-
come measures used in clinical trials of dcSSc (11). This
1-year observational study found that physician global
assessment of health correlates with objective measure-
ments of skin involvement in addition to many other phy-
sician- and patient-reported assessments, while patient
global health assessment has large correlations with pa-
tient-reported skin interference in daily activities and the
PCS of the SF-36 questionnaire. In addition, MRSS and
physician- and patient-reported skin variables were re-
sponsive to change. For musculoskeletal variables, only
serum CPK and tender joint count showed responsiveness
to change while contractures did not change. However, the
musculoskeletal measures were less responsive than skin
measures.
Hudson et al evaluated 803 patients with SSc and also
reported that physician assessments of the overall disease
condition in SSc patients are associated with objective
skin measures, while patient assessments of overall dis-
ease are inﬂuenced by more subjective factors such as
pain, fatigue, gastrointestinal symptoms, and other mani-
festations that affect HRQOL (28). The inﬂuence of objec-
tive skin symptoms on physician assessments of overall
disease is likely due to evidence in the literature showing
that, for dcSSc, skin involvement is predictive of mortality
and is associated with internal organ involvement (22).
Also, the use of MRSS is common as the primary/second-
ary outcome measure in multiple clinical trials (14,29,30).
These ﬁndings, along with our ﬁndings on the responsive-
ness to change, support the conclusion that MRSS is a
good indicator of improvement or progression in SSc and
is a suitable measure for use in clinical trials. In addition,
durometer measurement was found to be feasible, as 68%
of participants had a baseline evaluation in this multi-
center cohort, which is consistent with a previous clinical
trial (17). In the current study, there was a large correlation
(r  0.69) between durometer and MRSS at baseline.
In general, skin measures had higher correlations with
patient and physician measures of global health and were
more responsive to change compared to musculoskeletal
measures. In addition, physician assessment of global
health correlated more highly with physician-reported
skin involvement in the last month and MRSS. However,
patient global assessment had large correlation with pa-
tient-reported skin condition interference and moderate
correlation with MRSS, suggesting that, while objective
skin involvement and severity has a greater effect on phy-
sician assessment of disease, skin interference with daily
life and MRSS are both important for the patient.
Previous studies have suggested that musculoskeletal
involvement is concerning to patients with dcSSc (8,31).
For example, Clements et al found a signiﬁcant correlation
between HAQ DI and various musculoskeletal symptoms,
including hand problems, small joint contractures, and
tendon friction rubs (22). Change in tendon friction rubs
has also been shown to predict change in HAQ DI (23).
However, our data suggest that both physicians and pa-
tients consider skin involvement and impact of skin on
day-to-day activity as contributing more to overall disease
assessment than musculoskeletal involvement. The HAQ
DI was the only variable with moderate correlations with
physician and patient global assessments. MRSS and HAQ
DI have a large correlation of 0.39, a ﬁnding consistent
with a prior report (22).
The ability of HRQOL instruments to detect clinically
important changes is crucial to their usefulness in deter-
mining the effectiveness of different therapies (20,32). The
magnitude of responsiveness as measured by these instru-
ments is useful in assessing treatment efﬁciency and as-
sessing sample size for future trials. Responsiveness to
change was larger for skin variables compared to muscu-
loskeletal variables suggesting that skin variables (both
objective and subjective) are better outcome measures for
clinical trials.
The CRISS cohort is generally representative of patients
enrolled in large multicenter random controlled trials
(RCTs) of dcSSc when compared to the combined data
from 3 large RCTs in dcSSc (33). The combined trial pop-
ulation had a similar mean age (48 years versus 50 years in
CRISS), disease duration (27 months versus 19 months in
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CRISS), MRSS (25.3 versus 20.6 units in CRISS), tender
joint count (1.3 versus 1.3 in CRISS), HAQ DI (1.2. versus
1.0 in CRISS), and physician global assessment (4.7 versus
4.3).
Our study has several strengths. First, it provides data
on 200 patients with early dcSSc collected at 4 expert
scleroderma centers. Second, it carefully evaluated out-
come measures endorsed by experts in SSc via an interna-
tional Delphi and nominal group technique (12). Third, we
employed anchors to assess responsiveness to change for
the outcome measures.
The current study also has some limitations. First, in-
formation about treatment was not collected at baseline or
at followup. Treatment is a possible confounder for the
current analyses since patients with more severe symp-
toms at baseline might have been treated more aggres-
sively, resulting in a greater improvement over the 1-year
study. However, the effect of treatment is beyond the scope
of this analysis. The purpose of the current study was to
assess performance of skin and musculoskeletal variables
independent of treatment. Second, evaluations were per-
formed at baseline and 1 year with no intervening evalu-
ations, which did not allow time-series analysis; however,
the correlations and anchors allowed us to ascertain re-
sponsiveness despite this. Third, the present data apply
only to relatively early dcSSc and do not address the
utility of these variables and their relation to other out-
comes in patients with later, atrophic dcSSc nor to those
with limited SSc.
In conclusion, in a multicenter early dcSSc cohort we
found that physician global assessment and patient global
assessment are associated with both objective (MRSS) and
subjective assessments of skin severity and interference
with skin involvement, although the strength of associa-
tions was different. Both assessments accounted for phys-
ical disability as assessed by the SF-36 PCS and HAQ DI.
Our data offer strong support for the use of MRSS as an
outcome measure in dcSSc. Other measures will likely
apply in other clinical circumstances.
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